Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
03 Jun 2021
Historique:
received: 09 04 2021
revised: 28 05 2021
accepted: 28 05 2021
entrez: 2 7 2021
pubmed: 3 7 2021
medline: 14 7 2021
Statut: epublish

Résumé

The FcγRIIA/CD32A is mainly expressed on platelets, myeloid and several endothelial cells. Its affinity is considered insufficient for allowing significant binding of monomeric IgG, while its H131R polymorphism (histidine > arginine at position 131) influences affinity for multimeric IgG2. Platelet FcγRIIA has been reported to contribute to IgG-containing immune-complexe clearance. Given our finding that platelet FcγRIIA actually binds monomeric IgG, we investigated the role of platelets and FcγRIIA in IgG antibody elimination. We used pharmacokinetics analysis of infliximab (IgG1) in individuals with controlled Crohn's disease. The influence of platelet count and FcγRIIA polymorphism was quantified by multivariate linear modelling. The infliximab half-life increased with R allele number (13.2, 14.4 and 15.6 days for HH, HR and RR patients, respectively). It decreased with increasing platelet count in R carriers: from ≈20 days (RR) and ≈17 days (HR) at 150 × 10

Identifiants

pubmed: 34205175
pii: ijms22116051
doi: 10.3390/ijms22116051
pmc: PMC8199937
pii:
doi:

Substances chimiques

Antigen-Antibody Complex 0
Fc gamma receptor IIA 0
Immunoglobulin G 0
Receptors, IgG 0
Infliximab B72HH48FLU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Clin Oncol. 2008 Nov 20;26(33):5489-91; author reply 5491-2
pubmed: 18955438
Blood. 2018 Apr 5;131(14):1512-1521
pubmed: 29475962
Nature. 1989 Jan 12;337(6203):184-7
pubmed: 2911353
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32658257
Ther Drug Monit. 2006 Apr;28(2):169-74
pubmed: 16628126
Nat Commun. 2011 Dec 20;2:599
pubmed: 22186895
Front Immunol. 2020 Feb 05;11:118
pubmed: 32117269
Adv Immunol. 2009;103:77-115
pubmed: 19755184
Immunol Res. 2002;25(2):97-113
pubmed: 11999172
Mol Immunol. 2011 Jan;48(4):691-6
pubmed: 21168221
Sci Rep. 2017 Mar 13;7:44356
pubmed: 28287163
Front Immunol. 2019 Jul 10;10:1540
pubmed: 31354709
Exp Hematol. 2006 Nov;34(11):1490-5
pubmed: 17046568
J Clin Invest. 1985 Dec;76(6):2317-22
pubmed: 2934409
J Immunol. 2004 Jul 1;173(1):332-9
pubmed: 15210791
Nat Rev Immunol. 2007 Sep;7(9):715-25
pubmed: 17703228
J Clin Invest. 1970 Apr;49(4):673-80
pubmed: 5443170
Blood. 2014 Dec 11;124(25):3709-18
pubmed: 25352126
Clin Pharmacokinet. 2015 May;54(5):551-62
pubmed: 25516415
J Immunol. 2011 Apr 15;186(8):4674-86
pubmed: 21402891
J Clin Invest. 1989 Feb;83(2):355-61
pubmed: 2643627
Thromb Res. 2014 Mar;133(3):426-32
pubmed: 24440139
J Clin Invest. 1992 Oct;90(4):1537-46
pubmed: 1401085
Cancer Res. 2004 Jul 1;64(13):4664-9
pubmed: 15231679
Clin Exp Immunol. 1983 May;52(2):423-9
pubmed: 6602680
Blood. 2015 Apr 9;125(15):2397-404
pubmed: 25680756
Immunol Rev. 2015 Nov;268(1):253-68
pubmed: 26497526
J Immunol. 1991 Aug 15;147(4):1338-43
pubmed: 1831223
Mol Immunol. 2003 Dec;40(9):585-93
pubmed: 14597161
Front Immunol. 2019 Jun 06;10:1297
pubmed: 31244843
Sci Rep. 2019 May 14;9(1):7363
pubmed: 31089170
J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):341-51
pubmed: 19578985
Nature. 1964 Sep 26;203:1352-4
pubmed: 14207307
Gastroenterology. 2012 Jan;142(1):63-70.e5; quiz e31
pubmed: 21945953
Proc Natl Acad Sci U S A. 1996 May 28;93(11):5512-6
pubmed: 8643606
J Immunol. 1989 Sep 1;143(5):1731-4
pubmed: 2527271
Eur J Immunol. 1996 Mar;26(3):690-6
pubmed: 8605939
Blood. 2006 Nov 15;108(10):3573-9
pubmed: 16849638
Am J Pathol. 2013 Jan;182(1):244-54
pubmed: 23141924
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1359-63
pubmed: 15860734
Clin Exp Immunol. 1998 Jun;112(3):533-8
pubmed: 9649226
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
J Pharmacokinet Pharmacodyn. 2001 Dec;28(6):507-32
pubmed: 11999290
MAbs. 2019 Jul;11(5):848-860
pubmed: 30964743

Auteurs

Gilles Thibault (G)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire d'Immunologie, CHRU de Tours, 37032 Tours, France.

Gilles Paintaud (G)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, 37044 Tours, France.

Hsueh Cheng Sung (HC)

EA 7501 GICC, Université de Tours, 37032 Tours, France.

Laurie Lajoie (L)

EA 7501 GICC, Université de Tours, 37032 Tours, France.

Edouard Louis (E)

Department of Gastroenterology, University Hospital, CHU of Liège, 4000 Liège, Belgium.

Celine Desvignes (C)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, 37044 Tours, France.

Hervé Watier (H)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire d'Immunologie, CHRU de Tours, 37032 Tours, France.

Valérie Gouilleux-Gruart (V)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire d'Immunologie, CHRU de Tours, 37032 Tours, France.

David Ternant (D)

EA 7501 GICC, Université de Tours, 37032 Tours, France.
Laboratoire de Pharmacologie-Toxicologie, CHRU de Tours, 37044 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH